AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10788542
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 10 mg/week
Trial: 15811207
Drug: Zolmitriptan 2.5
RxNorm normalized name: zolmitriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 2.5 mg ODT
Trial: 25693652
Drug: 1.2-mL bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2-mL bolus injection over 5 s
Trial: 25693652
Drug: 3.5-mL injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5-mL injection over 1 min
Trial: 25693652
Drug: 3.5-mL injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5-mL injection over 4 min
Trial: 25693652
Drug: 3.5-mL injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5-mL injection over 10 min
Trial: 25693652
Drug: 3.5-mL injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5-mL injections
Trial: 25693652
Drug: 1.2-mL injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2-mL injections
Trial: 25693652
Drug: 4-min injections
RxNorm normalized name: gallamine
DrugBank: Gallamine (DB13584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-min injections
Trial: 25693652
Drug: 1-min injections
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-min injections
Trial: 25693652
Drug: 10-min injections
RxNorm normalized name: fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-min injections
Trial: 21718484
Drug: Ginseng capsule
RxNorm normalized name: Nature's Way Asian Ginseng Capsules
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng capsule (100 mg) twice daily for 24 weeks
Trial: 21718484
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo twice daily for 24 weeks
Trial: 18829631
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone phosphate
Trial: 8418403
Drug: Nucleus multichannel
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus multichannel implant (implant 2)
Trial: 8418403
Drug: Ineraid multichannel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ineraid multichannel implant (implant 1)
Trial: 8418403
Drug: 3M/Vienna single‐channel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3M/Vienna single‐channel implant (implant 3)
Trial: 8418403
Drug: Nucleus multichannel
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus multichannel implant (implant 2) with improved speech processor
Trial: 26663687
Drug: mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirabegron 50 mg
Trial: 26663687
Drug: mirabegron 100
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mirabegron 100 mg
Trial: 31526207
Drug: Ketamine (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.25, 0.5, 1 mg/kg) administered at weekly intervals
Trial: 31526207
Drug: Midazolam (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.01 mg/kg)
Trial: 20890176
Drug: Thrombolysis (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis (100 mg of alteplase: 10 mg bolus followed by 90 mg intravenous infusion over 2 hours)
Trial: 20890176
Drug: Thrombolysis (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis (100 mg of alteplase)
Trial: 3536261
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg methylprednisolone
Trial: 3536261
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg methylprednisolone
Trial: 30146282
Drug: 125 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 g/d of regular cheese for 2 weeks
Trial: 20546674
Drug: BMMC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMMC injection into the left ventricular free wall
Trial: 30089135
Drug: Galantamine 4
RxNorm normalized name: galantamine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 4 mg
Trial: 30089135
Drug: Galantamine 8
RxNorm normalized name: galantamine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 8 mg
Trial: 12211216
Drug: Galantamine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (4 mg and 8 mg)
Trial: 492050
Drug: Propranolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.1 mg/kg)
Trial: 8831364
Drug: Procainamide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (15 mg/kg)
Trial: 2008800
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with a highly purified, inactivated virus particle vaccine
Trial: 26088378
Drug: Ivabradine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 10 mg or 15 mg
Trial: 24759957
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment plus a theory‐based behaviour change intervention led by a facilitator
Trial: 22689805
Drug: Decitabine 20
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m² per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks
Trial: 22689805
Drug: Treatment choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment choice (TC) - supportive care or cytarabine 20 mg/m² per day as a subcutaneous injection for 10 consecutive days every 4 weeks
Trial: 22689805
Drug: Treatment choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment choice (TC)
Trial: 19424073
Drug: Gabapentin (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1.2 g oral, single dose 1 hour before surgery)
Trial: 16697113
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy regimen including active exercises (10 appointments within 14 days)
Trial: 16697113
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (immobilization with a soft collar for 7 days)
Trial: 15265256
Drug: Abacavir (ABC)
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abacavir (ABC) 300 mg plus fixed-dose lamivudine 150 mg/zidovudine 300 mg (COM) twice daily
Trial: 15265256
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indinavir (IDV) plus COM twice daily
Trial: 9160758
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR (180 mg)
Trial: 9160758
Drug: Trandolapril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (1 mg)
Trial: 9160758
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR + Trandolapril (fixed combination)
Trial: 7961013
Drug: Multileaf collimator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multileaf collimator combined with three-dimensional treatment planning
Trial: 7961013
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment with photons
Trial: 29721715
Drug: No locoregional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No locoregional treatment (no-LRT)
Trial: 9717015
Drug: Low-dose sotalol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sotalol (selective approach)
Trial: 2921096
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg Ro 16-6028
Trial: 2921096
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg Ro 16-6028
Trial: 2921096
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg Ro 16-6028
Trial: 1168170
Drug: Live, attenuated
RxNorm normalized name: Ebola Zaire vaccine (live, attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, attenuated recombinant influenza vaccine (Alice strain) administered intranasally
Trial: 1168170
Drug: Subcutaneous, inactivated,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous, inactivated, bivalent influenza vaccine
Trial: 31677046
Drug: Monthly lifestyle
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly lifestyle education program including advice on nutritional changes and physical activity enhancement.
Trial: 31677046
Drug: Attention-control group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-control group receiving monthly lectures on non-cardiovascular topics with verbal advice on healthy diet and exercise.
Trial: 25982601
Drug: Dorzolamide, three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide, three times daily for three weeks
Trial: 25982601
Drug: Placebo, three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, three times daily for three weeks
Trial: 23952999
Drug: ivabradine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine (15 mg/day for 50% of patients, 10 mg/day for 28%)
Trial: 20948195
Drug: Intratympanic (IT)
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic (IT) methylprednisolone injection
Trial: 20948195
Drug: Blank control
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank control (no treatment)
Trial: 19637947
Drug: Fosamprenavir 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosamprenavir 1400 mg once/day
Trial: 19637947
Drug: Atazanavir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 400 mg once/day
Trial: 19637947
Drug: Fosamprenavir 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosamprenavir 1400 mg plus Atazanavir 400 mg once/day
Trial: 16293317
Drug: Amoxicillin-clavulanate (45/6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (45/6.4 mg/kg/day in two divided doses for 10 days)
Trial: 15156472
Drug: Echinacea purpurea,
RxNorm normalized name: Echinacea purpurea,angustif xt 125 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea purpurea, 2.5 mL 3 times per day for 7 days before and 7 days after inoculation
Trial: 15156472
Drug: Placebo, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2.5 mL 3 times per day for 7 days before and 7 days after inoculation
Trial: 11288041
Drug: Alcohol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.4 g/kg body weight)
Trial: 8323333
Drug: subcutaneous human
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous human recombinant erythropoietin (r‐HuEpo)
Trial: 3090274
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pethidine and hyoscine butyl bromide
Trial: 20042440
Drug: Gentler words
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentler words for administration of the local anesthetic
Trial: 20042440
Drug: Harsher nocebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harsher nocebo words for administration of the local anesthetic
Trial: 18378354
Drug: Terbinafine (5‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (5‐8 mg/kg)
Trial: 18378354
Drug: Griseofulvin (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (10‐20 mg/kg)
Trial: 18378354
Drug: Terbinafine (5‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (5‐8 mg/kg) in trial 1
Trial: 18378354
Drug: Griseofulvin (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (10‐20 mg/kg) in trial 1
Trial: 18378354
Drug: Terbinafine (5‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (5‐8 mg/kg) in trial 2
Trial: 18378354
Drug: Griseofulvin (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (10‐20 mg/kg) in trial 2
Trial: 18378354
Drug: Terbinafine (5‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (5‐8 mg/kg) for T. tonsurans
Trial: 18378354
Drug: Griseofulvin (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (10‐20 mg/kg) for M. canis
Trial: 7638926
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Heparin and physical methods)
Trial: 2692823
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate (2 gm daily)
Trial: 2692823
Drug: Clavulanate‐potentiated amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clavulanate‐potentiated amoxicillin (1.125 gm daily)
Trial: 31042621
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (waiting list, no treatment, n = 25)
Trial: 22964882
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) at a dose of 5 mg on day 1 of each course of low-dose Ara-C (LDAC)
Trial: 22964882
Drug: Low-dose Ara-C
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Ara-C (LDAC) alone
Trial: 22040189
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) at a target dose of 1.2 mg/kg/day for 8 weeks
Trial: 19402154
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (75 mg/day for 2 months)
Trial: 8875537
Drug: Low calorie/low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calorie/low fat intravenous solution (C)
Trial: 6340444
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (5 mg)
Trial: 22855917
Drug: Modified hypocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified hypocaloric diet (MHCD) with high-protein, low-glycemic load (30% of daily energy from protein)
Trial: 22855917
Drug: Conventional hypocaloric
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hypocaloric diet (CHCD) (15% of daily energy from protein)
Trial: 15867002
Drug: Antioxidant treatment
RxNorm normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant treatment (1 g vitamin C and 1 g vitamin E daily for 2 months)
Trial: 12236630
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units subcutaneous IFN-alpha
Trial: 31881911
Drug: Multimodal manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal manual therapy (MT) treatment
Trial: 26891118
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (150 μg of iodine as potassium iodate daily for 24 weeks)
Trial: 19125778
Drug: Alogliptin 12.5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg and 25 mg
Trial: 10522993
Drug: Ibandronate infusion
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate infusion (dosage not specified)
Trial: 1659253
Drug: Esmolol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (1.0 mg/kg)
Trial: 1659253
Drug: Labetalol (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (0.3 mg/kg)
Trial: 1952135
Drug: Lidocaine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.0 mg/kg)
Trial: 17709710
Drug: TCH346 (1.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCH346 (1.0, 2.5, 7.5, or 15 mg/day)
Trial: 8042757
Drug: flunitrazepam/fentanyl (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flunitrazepam/fentanyl (0.01 mg/kg for induction, 1.2 mg/h for maintenance)
Trial: 8042757
Drug: etomidate (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etomidate (0.25 mg/kg) and fentanyl (0.005 mg/kg) for induction, isoflurane (0.6‐1.2 vol%)/fentanyl (1.2 mg/h) for maintenance
Trial: 3381314
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antimalarial agents)
Trial: 6353843
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid treatment
Trial: 22623383
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula (4 mg iron/L, 13.1 g protein/L)
Trial: 17848393
Drug: ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril (5 mg BID)
Trial: 16392975
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy plus cognitive-behavioral (MET-CB) treatment
Trial: 12399280
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake from diet plus supplements
Trial: 12399280
Drug: Urinary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary iodine excretion measured as a concentration
Trial: 10467958
Drug: H2‐receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2‐receptor antagonist (n = 196)
Trial: 10467958
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (n = 116)
Trial: 7826063
Drug: UFT combined
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT combined therapy group (UFT, DESP, and castration)
Trial: 7826063
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy alone group (DESP and castration)
Trial: 1369703
Drug: Nicardipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (60 mg daily)
Trial: 7000228
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole
Trial: 27759074
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg or 400 mg γδ‐T3 emulsions
Trial: 26026286
Drug: Bromocriptine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine therapy (2.5 mg b.i.d. for 14 days and 2.5 mg q.d. from day 15 to 56) plus best supportive care (BSC)
Trial: 26026286
Drug: Best supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care (BSC) plus 1 week of low-dose bromocriptine (2.5 mg q.d.) with anticoagulant therapy at a prophylactic dose
Trial: 23375680
Drug: DPP-IV inhibitors
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP-IV inhibitors (sitagliptin and vildagliptin)
Trial: 22443213
Drug: DPP-IV inhibitors
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP-IV inhibitors
Trial: 20553148
Drug: Amoxicillin antibiotic
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin antibiotic prophylaxis
Trial: 20553148
Drug: Different amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different amoxicillin regimens
Trial: 19436275
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication group receiving 1-week triple therapy (n=105)
Trial: 31129930
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg
Trial: 14993498
Drug: Citrate-taurolidine-containing solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate-taurolidine-containing solution
Trial: 11240235
Drug: Long-term hormones
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term hormones (LTH) - goserelin starting the last week of RT and continued indefinitely.
Trial: 11240235
Drug: Short-term hormones
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term hormones (STH) - goserelin and flutamide 2 months prior to and during RT.
Trial: 11240235
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) alone.
Trial: 8070927
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg fluconazole orally over 5 days